Navigation Links
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
Date:3/25/2010

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense (DoD) Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

David Taylor-Fishwick, PhD, associate professor of internal medicine and director of the Cell, Molecular and Islet Biology Laboratory, leads the team whose research applies to both regenerative and autoimmune medicine.

"Type 1 diabetes is caused by an autoimmune attack that destroys the insulin-producing beta cells, and the body does not automatically regenerate or replace these cells," explains Dr. Taylor-Fishwick. "The unique challenge in reversing Type 1 diabetes is to regenerate the insulin-producing beta cells and to stop the body's autoimmune attack."

Insulin is the hormone that helps the body convert glucose from food into energy. When the beta cells are destroyed, no insulin can be produced. Insulin replacement therapy helps the body maintain normal glucose levels, but doesn't prevent the serious diabetes health problems such as blindness, nerve damage, heart disease and kidney failure.

Dr. Taylor-Fishwick's research on beta cell regeneration has focused on INGAP (Islet Neogenesis Associated Protein), branded as Exsulin, the breakthrough discovery made by Aaron I. Vinik, PhD, MD, director of research at the Strelitz Diabetes Center, and Dr. Lawrence Rosenberg of McGill University. Published trials of Exsulin demonstrated promising results in both Type 1 and Type 2 diabetes patients.

The DoD grant will fund the next phase in the team's research finding a way to neutralize the immune system's attack of the beta cells. This immune attack occurs at the onset of diabetes and may continue after Type 1 diabetes has appeared. The benefits of this research may also apply to other autoimmune diseases such as lupus and rheumatoid arthritis.

Dr. Taylor-Fishwick and his team will test several experimental drugs developed by Jerry Nadler, MD, chair of internal medicine and director of the EVMS Strelitz Diabetes Center. The compounds are designed to modify the autoimmune response and stabilize beta cells. The goal is to develop these compounds into an oral pill.

"The Department of Defense, through its Congressionally Directed Medical Research Program, is especially interested in research to combat autoimmunity," Dr. Taylor-Fishwick says. "So part of our work is to block the process of autoimmunity that occurs in diabetes. We are using a drug called Lisofylline (LSF) and related molecules to block interleukin-12, a protein that triggers the autoimmune response," he explains. "By targeting interleukin-12 signaling, we hope to redirect the immune system, but not wipe it out."

The researchers hope that one of these compounds, when used in conjunction with Exsulin, may help to create a combination therapy regimen that could achieve a functional cure for Type 1 diabetes.


'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-7070
Eastern Virginia Medical School
Source:Eurekalert  

Related medicine news :

1. US Wellness, Inc. Receives National Recognition for Laboratory Excellence
2. American Public Health Champion Receives 2010 Stockholm Water Prize
3. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
4. BUSM researcher receives prestigious young investigator award
5. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
6. Christiana Care Health Systems Darcy Burbage Receives Oncology Nursing Society Award
7. Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award
8. CoreObjects Receives Project Management Institutes Excellence Award for Diabetes Contribution
9. Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting
10. U.S. Senator Kit Bond Receives 2010 AOA Health Care Leadership Award
11. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
(Date:6/27/2016)... ... June 27, 2016 , ... ... professionals, announced today its affiliation with Tennessee Counseling Association. This new ... network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: